The objective of a Phase I trial with two agents is to find a set of maximum-tolerated dose combinations that yield a prespecified toxicity rate. In this article, we consider the case where several doses of one agent are fixed and the goal is to find the maximum-tolerated dose of the other agent to be used in combination with each of the doses of agent one. We propose a Bayesian design that uses a parsimonious working model for the dose-toxicity relationship. We show that the new design is more effective in identifying the maximum-tolerated combinations than one-dimensional designs applied at each dose level of one of the agents.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: